European Journal of Pharmacology 2008-06-10

Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.

Takuya Hirata, Yoshihiro Keto, Mari Nakata, Asako Takeuchi, Toshiyuki Funatsu, Shinobu Akuzawa, Masao Sasamata, Keiji Miyata

Index: Eur. J. Pharmacol. 587(1-3) , 281-4, (2008)

Full Text: HTML

Abstract

The effects of corticotropin releasing factor (CRF) and serotonin (5-HT)(3) receptor antagonists on intestinal water transport are not well understood. Hence, we established a CRF-induced abnormal water transport model in rat colon, and evaluated the effects of 5-HT(3) receptor antagonists including ramosetron, alosetron, and cilansetron, and the antidiarrheal agent loperamide, in this model. In addition, the effects of 5-HT(3) receptor antagonists and loperamide on abnormal defecation induced by CRF in rats were examined. Colonic water transport was measured in colonic loops in conscious rats. Centrally administered CRF (3-30 microg/kg) markedly decreased colonic fluid loss, whereas oral administration of ramosetron (3, 30 microg/kg), alosetron (300 microg/kg), cilansetron (300 microg/kg), or loperamide (3 mg/kg) significantly inhibited it. Ramosetron (1-10 microg/kg), alosetron (10-100 microg/kg), cilansetron (10-100 microg/kg), or loperamide (0.3-3 mg/kg) also showed dose-dependent inhibition of CRF-induced defecation in rats. These results suggest that 5-HT(3) receptors are involved in both abnormal colonic water transport and defecation induced by CRF, and that the inhibitory effects of 5-HT(3) receptor antagonists on CRF-induced abnormal defecation partly result from their ameliorating action on colonic water transport.


Related Compounds

Related Articles:

In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.

2010-07-26

[J. Chem. Inf. Model. 50(7) , 1304-18, (2010)]

Quantitative benefit-risk assessment using only qualitative information on utilities.

2012-01-01

[Med. Decis. Making 32(6) , E1-15, (2012)]

Clinical trials in irritable bowel syndrome: a review.

2013-03-01

[Rev. Recent Clin. Trials 8(1) , 9-22, (2013)]

Quality of life in patients with irritable bowel syndrome.

2011-08-01

[J. Clin. Gastroenterol. 45 Suppl , S98-101, (2011)]

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.

2008-05-01

[Clin. Ther. 30(5) , 884-901, (2008)]

More Articles...